Arcutis Biotherapeutics Inc (NASDAQ: ARQT)’s stock price has increased by 0.07% compared to its previous closing price of $13.75. However, the company has seen a -4.91% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-27 that Arcutis Biotherapeutics’ ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shifting away from steroids, positioning Arcutis to capture significant share, especially via primary care channels. Arcutis is financially strong, with over 30 months of cash runway and no anticipated need for equity dilution before reaching profitability in 2026.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
Company’s 36-month beta value is 1.85.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ARQT is 104.80M, and currently, short sellers hold a 17.79% ratio of that floaft. The average trading volume of ARQT on July 03, 2025 was 2.19M shares.
ARQT’s Market Performance
ARQT stock saw an increase of -4.91% in the past week, with a monthly gain of 2.08% and a quarterly increase of -8.14%. The volatility ratio for the week is 4.19%, and the volatility levels for the last 30 days are 4.59% for Arcutis Biotherapeutics Inc (ARQT). The simple moving average for the past 20 days is -0.62% for ARQT’s stock, with a 7.45% simple moving average for the past 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at -1.77% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Welgus Howard G., who sale 9,208 shares at the price of $13.84 back on Jul 01 ’25. After this action, Welgus Howard G. now owns 100,206 shares of Arcutis Biotherapeutics Inc, valued at $127,430 using the latest closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -0.57 for the present operating margin
- 0.88 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -0.61. The total capital return value is set at -0.48. Equity return is now at value -70.58, with -31.54 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is -7.26.
Currently, EBITDA for the company is -109.62 million with net debt to EBITDA at -0.54. When we switch over and look at the enterprise to sales, we see a ratio of 7.98. The receivables turnover for the company is 2.49for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.55.
Conclusion
In a nutshell, Arcutis Biotherapeutics Inc (ARQT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
